Simplexa™ VZV Swab Direct Kit

Fast and Accurate VZV Molecular Testing

Do you want to place an order or request a trial?

Discover More
KIT for Infectious Diseases



Varicella-zoster virus infection causes two clinically distinct forms of disease, depending on whether an individual is experiencing a primary (chickenpox) or secondary infection (shingles)1. Varicella-zoster virus is highly contagious, spread by exposure to an individual shedding virus from either a varicella or herpes zoster infection. The virus can be spread from person to person by direct contact, inhalation of aerosols from vesicular fluid of skin lesions of acute varicella or zoster and possibly through infected respiratory secretions that also may be aerosolized2.

Common complications of VZV infection are bacterial infections of the skin and soft tissue in children and pneumonia in adults. Severe complications include encephalitis, pneumonia (either direct viral pneumonia or secondary bacterial pneumonia), bronchitis (either viral bronchitis or secondary bacterial bronchitis), visceral dissemination (VZV infection of internal organs) and postherpetic neuralgia in immunocompromised individuals. Varicella-zoster virus can also complicate pregnancy; newborns of infected mothers have a small risk of developing congenital varicella syndrome or neonatal varicella2.

The clinical presentation of zoster can often be confused with the dermal distribution produced by HSV, and thus it is important to detect VZV rapidly for proper patient treatment and management. The diagnosis of these two diseases is usually made clinically. PCR can be used to provide rapid and sensitive detection of VZV DNA in properly collected specimens.

1. Albrecht MA. (2017, May 31). Diagnosis of varicella-zoster virus infection. UpToDate. Retrieved on 06/27/2018 from
2. Centers for Disease Control and Prevention. (2016). Chicken Pox (Varicella). Retrieved from 


Why to choose it

A CLIA moderate complexity assay for the direct detection of the VZV DNA Polymerase gene from only 50 µl of cutaneous and mucocutaneous swab specimens. The assay improves efficiency with a true sample-to-answer workflow without DNA extraction.



Reliable performance that you can count on

greater than 98% clinical agreement

The Simplexa™ VZV Swab Direct assay demonstrated high performance with excellent clinical agreement against another CE Marked NAAT.

SimplexaTM VZV Swab Direct Clinical Agreement Study
Sample TypeSample Type Positive % Agreement Negative % Agreement
Sample TypeAll (mucocutaneous and cutaneous swab specimens) Positive % Agreement98.4% (61/62)
95% CI: 91.4% to 99.7%
Negative % Agreement99.2% (117/118)
95% CI: 95.4% to 99.9%
Broad Coverage

Broad Coverage for Your Testing Needs

Our Simplexa VZV Swab Direct assay utilizes only 50 µl of cutaneous or mucocutaneous swab specimen. Broad coverage includes samples collected from lesion locations including:

  • anorectal
  • genital
  • nasal
  • ocular
  • oral
  • urethra
  • skin

Ordering info

Product Code Reactions

Simplexa VZV Swab Direct Kit

Code MOL3655 Reactions 24

Simplexa VZV Positive Control Pack

Code MOL3660 Reactions 10

Do you want to place an order or request a trial?

Discover More

Our repository

All the answers you need.
Access our database to find:
instructions for use, safety data sheets,
assay protocols and more.

Access our repository